Back to top
more

Anixa Biosciences (ANIX)

(Delayed Data from NSDQ)

$3.23 USD

3.23
237,263

+0.25 (8.39%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.26 +0.03 (0.93%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

by Zacks Equity Research

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates

by Zacks Equity Research

Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

by Zacks Equity Research

Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

by Zacks Equity Research

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y

by Zacks Equity Research

FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

by Zacks Equity Research

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

by Zacks Equity Research

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals

by Zacks Equity Research

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.

Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

by Zacks Equity Research

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.

Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up

by Zacks Equity Research

Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.

Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

Bears are Losing Control Over ANIXA BIOSCIENCES INC (ANIX), Here's Why It's a 'Buy' Now

by Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

by Zacks Equity Research

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.

ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Vir Biotechnology (VIR) Down on Influenza Study Failure

by Zacks Equity Research

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.

Apellis (APLS) Plunges on Safety Issues With Eye Treatment

by Zacks Equity Research

Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.